***Real-Time Stock Alerts - 3 Ways to Get the Best Alerts

Scanz
https://scanz.com › real-time-stock-alerts
Looking to get stock alerts for day trading opportunities? Here are 3 ways you can get fresh, actionable alerts every single day.


***How Setting Personal Alerts Can Improve Your Trading

Scanz
https://scanz.com › personal-trading-alerts
A trading alert provides you with a notification when a certain set of criteria has been triggered. In EquityFeed, you can set audio alerts, popup alerts, and ...

ZHUD - From The Board.... By MrNormall- Thursday, October 26, 2023 5:52:04 PM- Post# 19922

$ZHUD In a matter of 2 days
@BelisarianCusto
Verified The Profile, uploaded all Fins necessary for Pink Current and Announced Several Interested Parties for Merger into the Shell

Amazing work here and Super Clean shell with Great Share Structure.

https://otcmarkets.com/stock/ZHUD/disclosure

YCRM, Looks Promising....

https://x.com/jeffjamesnow?s=21&t=9Ho_XAQWr1IM8QGERTg7JQ

$HIRU - non dilutive thin. Nice ask slaps

$BNGO The 13 analysts offering 12-month price forecasts for Nio Inc have a median target of 23.68, with a high estimate of 87.85 and a low estimate of 6.29. The median estimate represents a +587.47% increase from the last price of 3.45. https://money.cnn.com/quote/forecast/forecast.html?symb=NIO

JFIL 18 million float. This gets locked up its dollar bound

$NIO Nio Pure Electric Vehicle Pursuing Expansion in Germany
Made in China, designed in Germany — NIO, a multibillion-dollar Chinese company is dubbed by many as an answer to Tesla, the American e-car manufacturer https://www.nio.com/en_DE/about

$NIO on CBS's 60 Minutes

$GYOG - Beautiful volume trip lotto play

Upzs - nice volume. Looking to rip!

$UNRG & $ADIA Shell Stocks With Cannabis Connections!

$UNRG Custodian Date: 10/04/19

$ADIA Custodian Hearing: 11/09/19


========================================================================



































































































































































































Custodian Shell Plays

$PBEC $GRYO $GNXP $REOS $DWIS $DKMR $ADIA $EVTP $AAST $TNPH $MCTC $CSOL $YBIN
$DCGD

David Lazar Shell Plays

$SHNL $PEIW $GLFW $OCBG $TRDX $REPO $IDAD $FHAI $NTAH
$XNNHQ $MSHFQ $CERPQ $ESRG $HIGR $WDIS $TTCS $WSGF $EROZ
$VDPH $USRI $SIPN $INNX $PFMS $NXPC $ILXP $DIEN $CRGE

Sub-Penny Bottom Play Ready To Run!

$AHIX $APTY $APYP $BBDA $BGFT $BMXC $BOTY $BTFL $CBDD $CLKA
$CMGO $COBI $DNAD $DRNG $ERBB $ETEK $FTEG $FTWS $GOIG $GXXM $HMNY
$LBSR $MJTV $NOUV $PCLI $PTOP $QSIM $RETC $SBES $SDVI $SRMX $TPNI
$TTCM $USMJ $VGID $LIBE
=================================================
#davidlazar #reversemerger #mj #marijuana #hemp #custodian #custodianship
#merger #pennystocks $DCGD $ZMRK $KRFG $PASO $fcel $ACRL $PAOG $LAHO $VRUS
$VYST $SHMP $NWBO $ADIA $CNWHF $HMLA $ADIA #marijuanastocks

Most Read Boards
$DCGD $FNMA $AVXL $COOP $AXXA $LIBE $CDIX $SNDD
$VYST $RNVA $NWBO $DEWM $PACV $VRUS $UNRG $KBLB
$LAHO $CVSI $FUNN $TTCM $TMDI $HDII $CLSI $PRED
$CNWHF $TRDX $LWLG $BIEL $EMPM $LFAP $HMLA $SFIO
$SOLI $HMNY $LQMT $FLES $PFMS $PCTL $CVM $IMTL
$DKSC $IPIX $VATE $RXMD $KGKG $CMGO $ACRL $PMCB

$XSNX

$HIHI - will be a nice runner. Hardly anything left on level 2s. RM and Acquisition talks

Holiday Island Holdings Is in Talks With M & A CandidatesPress Release | 06/06/2019

HOLIDAY ISLAND, Ark., June 06, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Holiday Island Holdings, Inc.  (OTCPink: HIHI) - a development stage company operating in the land development sector of the market - released the news today that it is in talks with a couple of Merger & Acquisition Candidates.
The Company is currently in talks with two different privately held companies about rolling them under HIHI.  One company is a resort management operation and the other company is in the recreational land development.

FCEL busting open

PRPO spiking again premarket

PRPO big day today day imho look at filings and insider buys wow

https://www.nasdaq.com/symbol/prpo/sec-filings

PRPO moving now!!!

PRPO nice climb today!

PRPO busting out premarket

>>>$BEMG Alert: PR on Uplisting Expert_NEW_Director to_help_with_UPLIST!

https://www.nasdaq.com/press-release/bemg-announces-dan-oran-as-new-officer--director-to-enhance-shareholder-value-20190409-00435

$GCGX keep an eye out here real company, real revs! The cannabis sector is going to take off! Don't get left behind.

EAPH - Easton Announces Signing of Joint Venture Agreement for the Purchase and Development of 9 Townhomes with Revenue in Excess of $4 Million and Provides Update on its Framing Contract with Revenues of $770K for Q1

Tuesday, April 2, 2019 9:00 AM

TORONTO, ON / ACCESSWIRE / April 2, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) Announces that is has signed a Joint Venture Agreement for the purchase and development of 9 townhomes in Welland, Ontario and provides update on its ongoing contract for the framing of 150 homes in Whitby, Ontario.
Easton is pleased to have signed a joint venture agreement for the purchase and development of 9 townhomes in Welland, Ontario, which is less than 30 minutes from Niagara Falls, Canada. The project will generate in excess of $4 million in revenues over the next 12 months and is scheduled to commence in the next 60 days, once all permits have been issued. This will be the second development project the Company has commenced, after its acquisition of approximately 3 acres in Cobourg, Ontario, where Easton is converting an existing heritage mansion into 6 luxurious residential condominium units, that will generate $2 million in profit for the Company and is expected to generate over $30 million over 3 years with the development of approximately 42 residential units.
Easton has achieved consistent revenues through its various operations and is growing its business daily. The Company has generated over $770,000 in the first quarter of 2019 from its framing contract alone, which it entered into in the last quarter of 2018 for the framing of 150 homes in Whitby, Ontario with a prominent local builder.
Easton further expects the launch of its women's health care products in Mexico in Q2 by multi-national Bayer, whereby Bayer will be making royalty payments to Easton and BMV, Easton's JV partner.
The Company also owns an interest in 135 acres in Georgina, Ontario and is working on a new plan for that property, which was appraised at over $8 million.
Easton has been seeing continued increase in its revenues from its various business initiatives and is committed to continuing to grow the business and realize extraordinary returns for the benefit of its shareholders and investors.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton, together with BMV Medica S.A. own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis, which they have sub-licensed to Bayer and Gedeon Richter. In addition, a generic cancer drugs line is being developed for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs. As part of its strategic growth plan, the Company has entered new lucrative market segments globally, including Gaming, Real Estate and Development, Food and Beverage and Cannabis.
For More Information on Easton Visit:
http://www.eastonpharmaceuticalsinc.com ;
http://finance.yahoo.com/q?s=eaph ;
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
CONTACT INFORMATION
Easton Pharmaceuticals, Inc. 
Tel: 647-362-5700 
Email: eastonpharma@protonmail.com
SOURCE: Easton Pharmaceuticals, Inc.
https://www.accesswire.com/540772/Easton-Announces-Signing-of-Joint-Venture-Agreement-for-the-Purchase-and-Development-of-9-Townhomes-with-Revenue-in-Excess-of-4-Million-and-Provides-Update-on-its-Framing-Contract-with-Revenues-of-770K-for-Q1

$FHAI - Low float. OTC Markets Company profile is getting updated. Company looks like its coming alive after 8 years. New Custodianship!

GNBT - FDA Approval

Wound Conforming Gel Matrix with Three Dosage Options

Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes

The 0.5 cc and 0.8 cc and 3.0 cc doses provide optimal wound coverage while reducing waste and costs

3 cc dose has utility in surgical applications for the treatment of larger wounds and surgical incisions

In negotiations with major surgical wound care networks for treatment of diabetic foot ulcers, venous stasis ulcers, and difficult to heal wounds

Nationally Renowned Wound Care Thought Leader, Dr. Peter A. Blume of Yale School of Medicine, provides insight

January 11, 2019 09:00 AM Eastern Standard Time

MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that Olaregen Therapeutix Inc., a subsidiary of Generex Biotechnology will launch three doses of FDA 510K-Cleared Excellagen, the company’s wound conforming gel matrix that is designated as a Cellular & Tissue Based Product or CTP for wound healing. The 0.5 cc and a 0.8 cc syringes will be utilized to treat smaller wounds such as diabetic foot ulcers, venous stasis ulcers, and pressure ulcers, and in patients who have undergone MOHs surgery for removal of cancerous tissue. The 3 cc syringe has been developed for larger wounds that are most frequently seen in emergency departments, operating rooms, and surgical suites. Excellagen has a designated reimbursement code in the Healthcare Common Procedure Coding System, with a unique Q Code designation 4149 referred to as a skin substitute.

“We’ve heard time and again about the issue of waste, or the need for multiple applications per a single procedure because the existing products don’t necessarily accommodate the size of the wound. This is not only time consuming for the doctor but is cost inefficient”

*Attention* $trep is a steal in these prices. Your own dd is needed to verify.

$$ PVSP $$ Word is ......MERGER COMING $$$ NICE !!

BBBAM !! FACT !!

$IMTV news! Nice partnership with 9 mile entertainment.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142722505

$IMTV Fast Facts; Don't forget them!
- New CEO
- No dilution
- Successful music event in Miami

$MNKD “We are pleased to have completed the TreT Phase 1 trial, which met the study’s safety, tolerability and pharmacokinetics objectives,” stated David Kendall, Chief Medical Officer of MannKind. “We are excited to utilize our existing technology platform and device capabilities to create an easy-to-use and tolerable formulation of treprostinil to help unmet patient needs in a serious chronic disease such as PAH.”

https://www.streetinsider.com/Corporate+News/MannKind+%28MNKD%29+Completes+Phase+1+Trial+of+Treprostinil+Technosphere+for+PAH+Advancing+Development+to+Next+Phase/14283663.html

$BLFR Info Just Posted Proving A Reverse Merger Is in Play!

$BLFR DD LINK

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141420796

TCEL DD Research Package -* Must Read*

The recent stock activity of TCEL coupled to the recent reinstatement of TCEL with Wyoming SOS, along with WE HAVE UNCOVERED BRAND NEW PATENTS & A BRAND NEW COMPANY (Fission Biomedical LLC and ContraVaccine LTD.) Strongly Suggesting that the research by Dr. Casey has been going full speed ahead behind the scenes.

The Reinstatement also suggests that along with all these new developments, there is news on the horizon of possible FDA approval for human trials for Therapy Cells & the possibility and bringing Mr. Casey's new company which shares TCEL Patents into the company as well maybe as an acquisition or Reverse Merger. Below is the research that would explain the current stock action and resurgence of volume and accumulation interest:

Therapy Cells, Inc. is a holding company. Their primary business focus and direction is applying Patent 8372644 and pursuing Therapy Cell related business. The company owned by Dr. Patrick Casey, Therapy Cells Limited (TCL), a New Zealand Corporation, was acquired by Therapy Cells Inc. (USA ) in August of 2011 for 3,000,000 Preferred C shares.





Therapy Cells, Inc. has been granted exclusive license to use Patent 8372644 for use in human applications. In 2013, the company had to cease trials due to lack of funding. The funding was in place in September 2015 via Soffinova Partners:

http://www.marketwired.com/press-release/therapy-cells-receives-funding-from-sofinnova-partners-advance-development-tissue-organ-otcqb-tcel-2057891.htm

The company has been quietly completing their research since! It's possible there were delays in receiving some of the funding, since it was coming from overseas (Paris), and it likely gets received as needed. Some NEW good news, just out last month from Sofinnova Partners, is that they have new funding for Biotech and Pharmaceutical companies estimated to be at least $375 million. Therapy Cell, Inc. in past PR stated that this was a long term funding agreement - as research is not a Fast process but an approach to science that requires tenacity and hard work, and the funding matter has to be out of the way which it has been during this time of dedicated silence in our opinion:


https://www.businesswire.com/news/home/20180403005874/en/Sofinnova-Partners-Launches-Healthcare-Crossover-Fund-%E2%82%AC275

Dr. Patrick Casey, who owns 3,000,000 preferred C shares via Therapy Cells, Limited (New Zealand) is also one of three beneficiary stockholders in Therapy Cells, Inc. He has been active.

In 2017 Casey was granted another NEW patent :


THIS YEAR In 2018, he applied for another new patent:


THE BIGGEST INTRIGUING NEWS IS THIS RECENT ACTIVITY: Dr. Patrick J. Casey has registered a new company in 2017 in the State of Kentucky. The company is called Fission Biomedical LLC. It is also listed on the Patent as the co-owner along with Transplantation Limited. Both are owned by DR. Casey:



https://patents.google.com/patent/US8372644


http://apps.sos.ky.gov/corpscans/60/0979760-06-99999-20170317-AOG-6748124-PU.PDF

$WNTR
.0003 X .0004
139M X 51M

RXMD-https://askwarrenbuffet.blogspot.ca/2018/02/the-best-investment-for-2018-is.html

Looking for a stock trading "alert" service.

Specifically RSI alerts. Email, text, or both.

I use Fidelity and TDAmeritrade. Looked at Think or Swim again. Way too complicated. Not user friendly or intuitive enough for me.

I am looking at Stock Monitor. So far looks good, but comes with a $14.95 monthly subscription.

Thoughts?

$AHIX Security Details
Share Structure
Market Value1 $347,120 a/o Jan 17, 2018

Authorized Shares 3,946,821,989 a/o Jan 02, 2018

Outstanding Shares 3,471,202,631 a/o Jan 02, 2018
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 2,748,383,689 a/o Aug 11, 2017
Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent

$NOUV ~ $NOUV - Articles
Indoor Air Quality: Ventilation by Demand



Greener Dorms - Case Study



A Framework for Converting Hotel Guestroom Energy Management into ROI



DLC Spec May Lead to Networked Control Rebates

Hey struck , i respect your tech analysis, i was wondering if the techs on APRU’s chart looks primed for a breakout or is it at its peak !

$CHIT !! Hot ! Bullish Shareholders Updates - http://globenewswire.com/news-release/2017/12/19/1266208/0/en/Cherubim-Interests-Inc-Address-To-Shareholders.html

$PPPMF *Primero Says 'On-Track' for 2017 Production Guidance

$ABCCF PR today! "ABcann Global Announces $30 Million Debenture Financing"

https://globenewswire.com/news-release/2017/11/27/1206208/0/en/ABcann-Global-Announces-30-Million-Debenture-Financing.html

7:00 AM ET 11/27/17 | GlobeNewswire

ABcann Global Announces $30 Million Debenture Financing

NAPANEE, Ontario, Nov. 27, 2017 (GLOBE NEWSWIRE) -- ABcann Global Corporation (TSXV:ABCN) ("ABcann" or the "Company") is pleased to announce that it has entered into a binding interim agreement with respect to a proposed private placement of convertible senior unsecured debentures (the "Debentures") in the aggregate principal amount of $30,000,000 (the "Financing").

The Debentures will:

-- mature on the date that is 36 months from the date of issuance;

-- bear interest at the rate of 7.0% per annum, computed on the basis of a 360-day year composed of twelve 30-day months, and payable semi-annually on the last day of June and December of each year, commencing on June 30, 2018;

-- be convertible, at the option of the holder, into common shares in the capital of the Company (each, a "Share") at a conversion price of $1.50 per Share; and

-- be convertible, at the option of the Company, into Shares if, at any time commencing four months plus one day following the closing date of the Financing, the daily volume weighted average trading price of the Shares on the TSX Venture Exchange (the "TSXV") (or such other stock exchange or quotation system as the Shares are then principally listed or quoted) for any consecutive 10 day trading period is greater than $2.25 per Share.

The proceeds of the Financing are expected to be used by the Company to make strategic acquisitions in the cannabis industry and for general working capital and corporate purposes.

"This financing will provide ABcann further capital to evaluate additional accretive opportunities as we strengthen our cash position to over $70 million," commented Barry Fishman, CEO and director of ABcann. "The stronger cash position will give us greater flexibility to execute our growth strategy, complete our current construction, and obtain larger-scale, cost-effective production capacity, which may include a greenhouse approach."

Completion of the Financing will be subject to various conditions, including execution of definitive agreements, the receipt of the approval of the TSXV, and the conversion of existing secured convertible debentures of the Company in the principal amount of $15 million into Shares in accordance with the terms thereof.

The Debentures, and the Shares into which the Debentures may be converted (collectively, the "Securities"), will be subject to restrictions on resale under applicable Canadian securities laws for a period of four months and one day from the closing of the Financing. None of the Securities have been or will be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would require registration or otherwise be unlawful.

About ABcann:

ABcann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products.

The Company is expanding its cultivation capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.

ON BEHALF OF THE BOARD OF DIRECTORS

"Barry Fishman"

Barry Fishman

CEO and Director

For further information, please contact Barry Fishman at barry.fishman@abcannglobal.com or Aaron Keay at aaron@abcannglobal.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Thnx Struk, $NOUV looks almost ready as well. 0001s almost finished. Grabbed some..

VPER They reinstated on Nevada SOS thats costly Plus they been running and growing the business this whole time they have unfortunately merely neglected the stock is all

http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=3tp6YOxlYG%252bPKVpMorq9OQ%253d%253d&CorpName=VIPER+NETWORKS%2c+INC

Plus they put out a news update in May which imo will be expanded on soon .. we'll see

http://www.vipernetworks.com/news/company-news/

Struk I see you have an interest in VPER. Whats the story there? Volume was crazy Friday.

$HTBX Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC

Ok thnx

APRU was called early November again at 0006 at TSL pvt chat

Below is the post on Nov 4th added to the watch list room



Struk
Nov-4 10:29 AM
-11.png
170K
APRU back on watch and bid / buy zone .0006/.0007 to likely test that 002 again
Weekly chart looks strong

Struck your feedback on apru please , because it seems something is happening

TSL has been in KNDI since 4.00 range it was alerted to all members at the end of summer in the pvt chat

$KNDI $7.69 + 0.5945 (8.37%)